Market closed
Scholar Rock/$SRRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Ticker
$SRRK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
128
Website
Scholar Rock Metrics
BasicAdvanced
$2.9B
-
-$2.63
0.51
-
Price and volume
Market cap
$2.9B
Beta
0.51
52-week high
$46.98
52-week low
$6.76
Average daily volume
1.4M
Financial strength
Current ratio
9.612
Quick ratio
9.316
Long term debt to equity
16.101
Total debt to equity
16.101
Interest coverage (TTM)
-36.87%
Management effectiveness
Return on assets (TTM)
-40.09%
Return on equity (TTM)
-82.95%
Valuation
Price to book
7.83
Price to tangible book (TTM)
7.83
Price to free cash flow (TTM)
-14.35
Growth
Earnings per share change (TTM)
20.30%
3-year earnings per share growth (CAGR)
-9.91%
What the Analysts think about Scholar Rock
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Scholar Rock Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Scholar Rock Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Scholar Rock News
AllArticlesVideos
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 days ago
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
Business Wire·4 weeks ago
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Scholar Rock stock?
Scholar Rock (SRRK) has a market cap of $2.9B as of April 22, 2025.
What is the P/E ratio for Scholar Rock stock?
The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of April 22, 2025.
Does Scholar Rock stock pay dividends?
No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of April 22, 2025.
When is the next Scholar Rock dividend payment date?
Scholar Rock (SRRK) stock does not pay dividends to its shareholders.
What is the beta indicator for Scholar Rock?
Scholar Rock (SRRK) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.